Fig. 1 · Structure

Documents & Downloads

Eliglustat

Cat. No. A12386 CAS 491833-29-5

Glucosylceramide synthase inhibitor

Eliglustat is a specific and potent inhibitor of glucosylceramide synthase.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
glucosylceramide synthase

Eliglustat Research Summary

This section summarizes 1 in vitro study and 3 in vivo studies of Eliglustat from 3 published references. In vitro models include MDA-MB-231 TNBC cells. In vivo models include fabry mice (α-galactosidase A knock-out); 8-week-old female C57BL/6J mice.

Eliglustat In Vitro Studies

MDA-MB-231 TNBC cells were treated with Eliglustat at 64 μM for a 6-h treatment. Mitochondrial area increased significantly compared with the vehicle (DMSO) control. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Mitochondrial area in TNBC cells

Cell-based study · MDA-MB-231 TNBC cells [1]

MDA-MB-231 TNBC cells received Eliglustat at 64 μM for a 6-h treatment. Mitochondrial area increased significantly compared with the vehicle (DMSO) control.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
mitochondrial areaReported result significant (Wilcoxon rank-sum test p < 0.05) increases in mitochondrial area[1]

Literature-Reported Treatment Conditions

Treatment concentration
64 μM
Exposure duration
6-h treatment
Vehicle
DMSO
Reported limits
Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: Eliglustat

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Inhibition of glucosylceramide synthase promotes mitochondrial lethality in breast cancer cells (S114, S123); STAR★Methods > Method details > Electron microscopy (S336)

mitochondrial area: mitochondrial area; comparator: vehicle (DMSO) control — Results > Inhibition of glucosylceramide synthase promotes mitochondrial lethality in breast cancer cells (S114)

Eliglustat In Vivo Studies

In Fabry mice, Eliglustat administered in food generally produced significant net GL-3 reductions of 40–50% in evaluated visceral tissues and whole blood, with no difference observed in brain between treated and untreated mice. In the urinary readout study, Eliglustat reduced urine GL-3 concentration to about 50% that of untreated Fabry mice. In female C57BL/6J mice, Eliglustat at 150 mg/kg/day in chow for 19 days significantly increased bone parameters, including bone volume over total volume (BV/TV), compared with normal chow controls. [2,3]

GL-3 reductions in visceral tissues of Fabry mice

Animal study · Fabry mice (α-galactosidase A knock-out) [2]

Treated Fabry mice received eliglustat tartrate as a component of their food beginning at 5 weeks of age; this formulation provided 300 mg/kg of eliglustat tartrate per day. Treated Fabry mice also continued to accumulate GL-3 throughout the course of the study, but did so at a reduced rate, generally resulting in significant net GL-3 reductions of 40–50% by the end of the study. One exception was the brain, where no difference was seen between treated and untreated mice.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
GL-3 levels in various tissuestissue GL-3 levels 300 mg/kg of eliglustat tartrate per day; liver, kidney, heart and spleen; whole blood; by the end of the study: GL-3 reductions of 40–50%[2]

Conditions shared by the study groups

Route
as a component of their food
Treatment course
beginning at 5 weeks of age
Vehicle
standard mouse chow
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Eliglustat 300 mg/kg of eliglustat tartrate per dayuntreated control Fabry300 mg/kg of eliglustat tartrate per day; visceral tissues evaluated (liver, kidney, heart and spleen) as well as whole blood: generally resulting in significant net GL-3 reductions of 40–50% by the end of the study. One exception was the brain, where no difference was seen between treated and untreated mice.[2]
Eliglustat 300 mg/kg of eliglustat tartrate per day
Model: Fabry mice (α-galactosidase A knock-out)
Methods and source locations

Compound reported in the paper: Eliglustat

Evidence for Eliglustat as the tartrate form reported in the paper, not the free base/neutral form supplied as A12386; no salt equivalence, dose conversion or lot validation.

Results > SRT reduces the rate of GL-3 accumulation in visceral tissues (S7, S8, S9); Materials and Methods > Animal Studies > Ethics Statement (S88); Materials and Methods > Treatment regimens (S97, S98); Figure 1 legend (S134, S135)

GL-3 levels in various tissues: GL-3 levels in various tissues; comparator: untreated control Fabry — Results > SRT reduces the rate of GL-3 accumulation in visceral tissues (S7, S8, S9); Materials and Methods > Treatment regimens (S98); Figure 1 legend (S135)

Eliglustat 300 mg/kg of eliglustat tartrate per day · Results > SRT reduces the rate of GL-3 accumulation in visceral tissues (S7, S8, S9); Materials and Methods > Treatment regimens (S98); Figure 1 legend (S134)

Bone parameters in female mice

Animal study · 8-week-old female C57BL/6J mice [3]

8-week-old female C57BL/6J mice received Eliglustat at 150 mg/kg/day in chow for 19 days. Bone parameters, including bone volume over total volume (BV/TV), increased significantly compared with normal chow controls.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
bone volume over total volume (BV/TV)Reported result a significant increase in bone parameters including bone volume over total volume (BV/TV)[3]

Conditions shared by the study groups

Route
eliglustat-containing chow
Treatment course
for 19 days
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Eliglustat 150 mg/kg/daynormal chow (Ctr, n = 6 biologically independent animals)a significant increase in bone parameters including bone volume over total volume (BV/TV)[3]
Eliglustat 150 mg/kg/day
Model: 8-week-old female C57BL/6J mice
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Eliglustat

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Eliglustat increases trabecular bone volume by inhibiting OCs in healthy mice (S1, S3); Fig. 1 legend (S303)

bone volume over total volume (BV/TV): bone volume over total volume (BV/TV); comparator: normal chow (Ctr, n = 6 biologically independent animals) — Results > Eliglustat increases trabecular bone volume by inhibiting OCs in healthy mice (S3)

Eliglustat 150 mg/kg/day · Results > Eliglustat increases trabecular bone volume by inhibiting OCs in healthy mice (S1, S3)

Urinary GL-3 response in Fabry mice

Animal study · Fabry mice [2]

Treated Fabry mice received eliglustat tartrate as a component of their food beginning at 5 weeks of age; this formulation provided 300 mg/kg of eliglustat tartrate per day. Treating Fabry mice with eliglustat tartrate (SRT) reduced the urine GL-3 concentration to about 50% that of the untreated mice.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Concentration of GL-3 in the urineurine GL-3 concentration about 50% that of the untreated mice[2]

Conditions shared by the study groups

Route
as a component of their food
Treatment course
beginning at 5 weeks of age
Vehicle
standard mouse chow
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Eliglustat 300 mg/kg of eliglustat tartrate per dayuntreated Fabry micereduced the urine GL-3 concentration to about 50% that of the untreated mice[2]
Eliglustat 300 mg/kg of eliglustat tartrate per day
Model: Fabry mice
Methods and source locations

Compound reported in the paper: Eliglustat

Evidence for Eliglustat as the tartrate form reported in the paper, not the free base/neutral form supplied as A12386; no salt equivalence, dose conversion or lot validation.

Results > SRT normalizes urine volume and decreases urine GL-3 levels (S21); Materials and Methods > Treatment regimens (S97, S98); Figure 2 legend (S138, S139, S141)

Concentration of GL-3 in the urine: Concentration of GL-3 in the urine; comparator: untreated Fabry mice — Results > SRT normalizes urine volume and decreases urine GL-3 levels (S21); Figure 2 legend (S141)

Eliglustat 300 mg/kg of eliglustat tartrate per day · Results > SRT normalizes urine volume and decreases urine GL-3 levels (S21); Materials and Methods > Treatment regimens (S98); Figure 2 legend (S138)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 491833-29-5
Applications Glucosylceramide synthase inhibitor
Formula C23H36N2O4
Molecular Weight 404.54
Synonyms Genz-99067
SMILES
CCCCCCCC(N[C@H](CN1CCCC1)[C@@H](C2=CC=C3OCCOC3=C2)O)=O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 77 mg/mL (190.33 mM)
Water Insoluble
Ethanol 77 mg/mL

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Eliglustat Research References

  1. [1] Vykoukal J, Chen Y, Zuo M, et al. Vesicle-mediated mitochondrial clearance presents an actionable metabolic vulnerability in triple-negative breast cancer. Cell Rep Med (2025). PMID: 41406946 DOI: 10.1016/j.xcrm.2025.102478 Source material
  2. [2] Marshall J, Ashe KM, Bangari D, et al. Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease. PLoS One (2010). PMID: 21124789 DOI: 10.1371/journal.pone.0015033 Source material
  3. [3] Leng H, Zhang H, Li L, et al. Modulating glycosphingolipid metabolism and autophagy improves outcomes in pre-clinical models of myeloma bone disease. Nat Commun (2022). PMID: 36550101 DOI: 10.1038/s41467-022-35358-3 Source material

Added to your cart

View Cart Checkout
Loading...